TickerKhojComparison · NSE · data 2026-11-03
Bafna Pharmaceuticals Limited vs Remus Pharmaceuticals Ltd.
In plain words
Size: Bafna Pharmaceuticals Limited is about 1.1 times the market value of Remus Pharmaceuticals Ltd..
Valuation (P/E): Bafna Pharmaceuticals Limited 133.4 vs Remus Pharmaceuticals Ltd. 26.5.
Profit growth over 3 years: Remus Pharmaceuticals Ltd. 63.2% a year vs Bafna Pharmaceuticals Limited -0.7% a year.
Debt to equity: Bafna Pharmaceuticals Limited 0.39 vs Remus Pharmaceuticals Ltd. 0.08.
Differences in the numbers, not a recommendation of either stock.
Side by side
| BAFNAPH | REMUS | |
|---|---|---|
| Price | ₹438.95 | ₹831 |
| Market cap | ₹1,060 cr | ₹994 cr |
| P/E | 133.4 | 26.5 |
| P/B | — | 2.8 |
| ROE | 12.3% | 12.2% |
| ROCE | 9.2% | 14.7% |
| Debt / equity | 0.39 | 0.08 |
| Operating margin | 3.7% | 6.3% |
| Dividend yield | 0.00% | 0.12% |
| Sales growth, 3 years (yearly) | 9.3% | 166.6% |
| Profit growth, 3 years (yearly) | -0.7% | 63.2% |
| 1-year return | 205.6% | 22.5% |
| Revenue, last 12 months | ₹143 cr | ₹854 cr |
| Net profit, last 12 months | ₹8 cr | ₹37 cr |
| Latest quarter | Jun 2026 | — |
| Quarter net profit | ₹0 cr | — |
| Quarter profit vs a year earlier | -97.6% | — |
| Promoter holding | 75.00% | — |
| Health check | Average (4.4/10) | Strong (7.9/10) |
Common questions
Which has a higher P/E, Bafna Pharmaceuticals Limited or Remus Pharmaceuticals Ltd.?
Bafna Pharmaceuticals Limited trades at the higher P/E (133.4 against 26.5). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Bafna Pharmaceuticals Limited (12.3% against 12.2%).
Which carries more debt?
Bafna Pharmaceuticals Limited has the higher debt-to-equity ratio (0.39 against 0.08).